SCHEMBL4069193

SCHEMBL4069193

CCC(=O)N(Cc1ccc2c(c1)OCO2)Cc1cc2ccccc2[nH]c1=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.75
ALDH1A1 P00352 11/20 0.75
HSD17B10 Q99714 5/20 0.75
HPGD P15428 6/20 0.69
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
GAA P10253 2/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
TSHR P16473 5/20 0.62
ALOX15 P16050 2/20 0.62
ESR1 P03372 1/20 0.62
HTT P42858 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
TDP1 Q9NUW8 1/20 0.59
USP2 O75604 2/20 0.58
MAPT P10636 5/20 0.58
POLB P06746 3/20 0.58
PKM P14618 2/20 0.58
ALOX12 P18054 1/20 0.58
FYN P06241 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4079906 0.87 FYN (0.61) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL4073895 0.82 KDM4E (0.64) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL5448947 0.82 KDM4E (0.66) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL4251806 0.77 KDM4E (0.59) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL4073262 0.76 ALDH1A1 (0.56) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL4070774 0.76 PKM (0.52) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL16491220 0.75 HSD17B10 (0.62) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL5443445 0.74 KDM4E (0.56) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL4077914 0.74 ALDH1A1 (0.55) KDM4EALDH1A1HSD17B10HPGDMEN1
SCHEMBL4391674 0.74 ALDH1A1 (0.53) KDM4EALDH1A1HSD17B10HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885ALDH1A1 1055/4885HSD17B10 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.